Ahn M-J et al. Osimertinib plus durvalumab in patients with EGFR-mutated, advanced NSCLC: A phase 1b, open-label, multicenter trial. J Thorac Oncol 2022;17(5):718-23. Abstract
Belluomini L et al. Anticipating EGFR targeting in early stages of lung cancer: Leave no stone unturned. Cells 2021;10(10):2685. Abstract
Burnett H et al. Epidemiological and clinical burden of EGFR exon 20 insertion in advanced non-small cell lung cancer: A systematic literature review. PLoS One 2021;16(3):e0247620. Abstract
Cheng ML et al. Plasma ctDNA response is an early marker of treatment effect in advanced NSCLC. JCO Precis Oncol 2021;5:PO.20.00419. Abstract
Cohen P et al. Kinase drug discovery 20 years after imatinib: Progress and future directions. Nat Rev Drug Discov 2021;20(7):551-69. Abstract
Cooper AJ et al. Third-generation EGFR and ALK inhibitors: Mechanisms of resistance and management. Nat Rev Clin Oncol 2022;19(8):499-514. Abstract
Felip E et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIA non-small-cell lung cancer (IMpower010): A randomised, multicentre, open-label, phase 3 trial. Lancet 2021;398(10308):1344-57. Abstract
Goto K et al. Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-mutant metastatic non-small-cell lung cancer (NSCLC): Interim results from the phase 2 DESTINY-Lung02 trial. ESMO 2022;Abstract LBA55.
Haikala HM, Jänne PA. 30 years of HER3: From basic biology to therapeutic interventions. Clin Cancer Res 2021;27(13):3528-39. Abstract
Jänne PA et al. Antitumor activity of sunvozertinib in NSCLC patients with EGFR exon20 insertion mutations after platinum and anti-PD(L)1 treatment failures. ASCO 2022;Abstract 9015.
Jänne PA et al. Efficacy and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC). ASCO 2021;Abstract 9007.
Jänne PA et al. Efficacy and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated non-small cell lung cancer. Cancer Discov 2022;12(1):74-89. Abstract
Jänne PA et al. Mobocertinib (TAK-788) in EGFR exon 20 insertion (ex20ins)+ metastatic non-small cell lung cancer (mNSCLC): Treatment (tx) beyond progressive disease (PD) in platinum-pretreated patients (pts) with and without intracranial PD. ASCO 2022;Abstract 9099.
Jänne PA et al. Phase 1 studies of DZD9008, an oral selective EGFR/HER2 inhibitor in advanced NSCLC with EGFR exon20 insertion mutations. IASLC 2022;Abstract OA15.02.
Jänne PA et al. Phase 1 study of patritumab deruxtecan (HER3-DXd; U3-1402) in combination with osimertinib in patients with advanced EGFR-mutated NSCLC. ASCO 2022;Abstract TPS3161.
Köhler J, Jänne PA. Amivantamab: Treating EGFR exon 20-mutant cancers with bispecific antibody-mediated receptor degradation. J Clin Oncol 2021;39(30):3403-6. Abstract
Krebs M et al. Amivantamab in patients with NSCLC with MET exon 14 skipping mutation: Updated results from the CHRYSALIS study. ASCO 2022;Abstract 9008.
Li BT et al. Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer. N Engl J Med 2022;386(3):241-51. Abstract
Majem M et al. Health-related quality of life outcomes in patients with resected epidermal growth factor receptor-mutated non-small cell lung cancer who received adjuvant osimertinib in the phase III ADAURA trial. Clin Cancer Res 2022;28(11):2286-96. Abstract
Mazieres J et al. Tepotinib + osimertinib for EGFRm NSCLC with MET amplification (METamp) after progression on first-line (1L) osimertinib: Initial results from the INSIGHT 2 study. ESMO 2022;Abstract LBA52.
Melosky B et al. The dawn of a new era, adjuvant EGFR inhibition in resected non-small cell lung cancer. Ther Adv Med Oncol 2021;13:1-15. Abstract
Nishino M et al. Prediction model for tumor volume nadir in EGFR-mutant NSCLC patients treated with EGFR tyrosine kinase inhibitors. J Thorac Imaging 2021;[Online ahead of print]. Abstract
Park K et al. Amivantamab in EGFR exon 20 insertion-mutated non-small-cell lung cancer progressing on platinum chemotherapy: Initial results from the CHRYSALIS phase I study. J Clin Oncol 2021;39(30):3391-402. Abstract
Passaro A et al. Overcoming therapy resistance in EGFR-mutant lung cancer. Nat Cancer 2021;2(4):377-91. Abstract
Peters S et al. The promising evolution of targeted therapeutic strategies in cancer. Cancer Discov 2021;11(4):810-4. Abstract
Piotrowska Z et al. ELIOS: A multicentre, molecular profiling study of patients (pts) with epidermal growth factor receptor-mutated (EGRm) advanced NSCLC treated with first-line (1L) osimertinib. ESMO 2022;Abstract LBA53.
Ramalingam SS et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med 2020;382(1):41-50. Abstract
Remon Masip J et al. Osimertinib treatment based on plasma T790M monitoring patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trial. ESMO 2022;Abstract LBA51.
Shu CA et al. Amivantamab and lazertinib in patients with EGFR-mutant non-small cell lung cancer (NSCLC) after progression on osimertinib and platinum-based chemotherapy: Updated results from CHRYSALIS-2. ASCO 2022;Abstract 9006.
Smit E et al. Trastuzumab deruxtecan in patients (pts) with HER2-overexpressing (HER2-OE) metastatic non-small-cell lung cancer (NSCLC): Results from the DESTINY-Lung01 trial. ESMO 2022;Abstract 975P.
Son J et al. A novel HER2-selective kinase inhibitor is effective in HER2 mutant and amplified non-small cell lung cancer. Cancer Res 2022;82(8):1633-45. Abstract
Sotelo MJ et al. Recent advances and new insights in the management of early-stage epidermal growth factor receptor-mutated non-small-cell lung cancer. World J Clin Oncol 2021;12(10):912-25. Abstract
Tsuboi M et al. Osimertinib as adjuvant therapy in patients (pts) with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC): Updated results from ADURA. ESMO 2022;Abstract LBA47.
Vokes NI et al. Concurrent TP53 mutations facilitate resistance evolution in EGFR-mutant lung adenocarcinoma. J Thorac Oncol 17(6):779-92. Abstract
Wang M et al. Sunvozertinib, a selective EGFR inhibitor for previously treated non-small cell lung cancer with EGFR exon 20 insertion mutations. Cancer Discov 2022;12(7):1676-89. Abstract
Wu Y-L et al. Postoperative chemotherapy use and outcomes from ADAURA: Osimertinib as adjuvant therapy for resected EGFR-mutated NSCLC. J Thorac Oncol 2022;17(3):423-33. Abstract
Yang J C-H et al. Sunvozertinib in NSCLC patients with EGFR exon20 insertion mutations: Effect of prior treatment. IASLC 2022;Abstract EP08.02-029.
Yu HA et al. ORCHARD osimertinib + savolitinib interim analysis: A biomarker-directed phase II platform study in patients (pts) with advanced non-small cell lung cancer (NSCLC) whose disease has progressed on first-line (1L) osimertinib. ESMO 2021;Abstract 1239P.
Yu H et al. Phase (ph) 1/2a study of CLN-081 in patients (pts) with NSCLC with EGFR exon 20 insertion mutations (ins20). ASCO 2022;Abstract 9007.
Zhou C et al. Treatment outcomes and safety of mobocertinib in platinum-pretreated patients with EGFR exon 20 insertion-positive metastatic non-small cell lung cancer: A phase 1/2 open-label nonrandomized clinical trial. JAMA Oncol 2021;7(12):e214761. Abstract